Assertio Holdings Inc. (NASDAQ:ASRT) Q2 2023 Earnings Call Transcript August 3, 2023 4:30 PM ET
Company Participants
Matt Kreps - Investor Relations
Dan Peisert - President and CEO
Paul Schwichtenberg - Senior Vice President and CFO
Tom Riga - Outgoing CEO of Spectrum Pharmaceuticals
Conference Call Participants
Thomas Flaten - Lake Street Capital Markets
Hamed Khorsand - BWS Financial Inc
Jim Sidoti - SIDOTI & Company
Scott Henry - Roth Capital
Operator
Good morning, and welcome to the Assertio Holdings Inc Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in -a listen-only mode. After today’s presentation there will be opportunity to ask questions. Please note, this event is being recorded.
I would like to turn the conference over to Matt Kreps from Darrow Associates, Investor Relations for Assertio. Please go ahead.
Matt Kreps
Good afternoon, and thank you, everyone, for joining us today to discuss Assertio second quarter 2023 financials. The news release covering our earnings rest period is now available on the Investor page of our website at nvestor.assertiotx.com. I would encourage you to review the release and tables in conjunction with today's discussion.
With me today are Dan Peisert, President and CEO; Paul Schwichtenberg, Senior Vice President and CFO; and Tom Riga, outgoing CEO of Spectrum Pharmaceuticals, for which we closed the acquisition of earlier this week. Dan will open remarks to provide an overview of the business. Tom will provide additional spectrum is open on progress, and Paul will review our financials.
After that, we'll open the call for your questions. During this call, management will make projections and other forward-looking statements regarding our future performance. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those noted in today's press release as well as Assertio's filings with the SEC.
These and other risks are more fully described in the Risk Factors section and other sections of our annual report on Form 10-K. Our actual results may differ materially from those projected in the forward-looking statements, and Assertio specifically disclaim intent or obligation to update those forward-looking statements, except as required by law.
And with that, I will now turn the call over to Dan.
Dan Peisert
Thank you, Matt. Good afternoon, everyone, and welcome to our new shareholders and employees from Spectrum Pharmaceuticals. The acquisition of Spectrum marks a significant turning point for Assertio, providing immediate diversification of revenues a sustainable near-term growth driver and long-term patent protection. The asset, the commercial infrastructure and sales model are also aligned with our vision of where we can effectively operate in this competitive pharmaceutical landscape our intelligent contracting and market access are the foundation of the go-to-market model.